SCOTT ALAN REINES
Medical Practice in New Hope, PA

License number
Pennsylvania MD022925E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
New Hope, PA 18938

Personal information

See more information about SCOTT ALAN REINES at radaris.com
Name
Address
Phone
Scott Reines, age 78
11 W Bridlewood Dr, New Hope, PA 18938
(215) 862-3282
Scott Reines
New Hope, PA
(215) 862-3282
Scott A Reines, age 78
11 Bridlewood Dr, New Hope, PA 18938
(215) 862-2290
(215) 862-3282

Professional information

Scott Reines Photo 1

Method Of Treating Migraines And Pharmaceutical Compositions

US Patent:
6384034, May 7, 2002
Filed:
Aug 22, 2001
Appl. No.:
09/934823
Inventors:
Kremena Simitchieva - Basking Ridge NJ
Scott A. Reines - New Hope PA
Errol McKinney - Doylestown PA
Deepak K. Khannna - Furlong PA
Richard Hargreaves - Terlings Park, GB
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
A61K 3150
US Classification:
514252, 514335, 514378, 514406, 514460
Abstract:
A combination of a 5HT agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.


Scott Reines Photo 2

Method For Treating Or Preventing Depression

US Patent:
2001004, Dec 6, 2001
Filed:
Feb 27, 2001
Appl. No.:
09/794197
Inventors:
Scott Reines - New Hope PA, US
Annette Robichaud - Montreal, CA
Frederick Tattersall - Bishops Stortford, GB
International Classification:
A61K031/5377
US Classification:
514/235800
Abstract:
A neurokinin-1 antagonist or an alpha-2 adrenoreceptor agonist provide an effective therapy in conjunction with a PDE4 inhibitor for the treatment or prevention of depression and/or anxiety. These combinations minimize the side effects of nausea and/or emesis associated with the PDE4 inhibitor and may also provide beneficial antidepressant and/or anti-anxiety effects.


Scott Reines Photo 3

Controlled Release Combination Of Carbidopa/Levodopa

US Patent:
4900755, Feb 13, 1990
Filed:
Feb 24, 1989
Appl. No.:
7/315057
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co. - Rahway NJ
International Classification:
A61K 920, A61K 922, A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.


Scott Reines Photo 4

Controlled Release Combination Of Carbidopa/Levodopa

US Patent:
4983400, Jan 8, 1991
Filed:
Dec 1, 1989
Appl. No.:
7/444222
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 922, A61K 926, A61K 3178
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.


Scott Reines Photo 5

Controlled Release Combination Of Carbidopa/Levodopa

US Patent:
4832957, May 23, 1989
Filed:
Jul 25, 1988
Appl. No.:
7/223861
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 920, A61K 922, A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.


Scott Reines Photo 6

Method For Treating Or Preventing Depression

US Patent:
2003002, Jan 30, 2003
Filed:
Aug 23, 2002
Appl. No.:
10/204876
Inventors:
Scott Reines - New Hope PA, US
Annette Robichaud - Montreal, CA
Frederick Tattersall - Bishops Stortford, GB
International Classification:
A61K031/00
US Classification:
514/001000
Abstract:
A neurokinin-1 antagonist or an alpha-2 adrenoreceptor agonist provide an effective therapy in conjunction with a PDE4 inhibitor for the treatment or prevention of depression and/or anxiety. These combinations minimize the side effects of nausea and/or emesis associated with the PDE4 inhibitor and may also provide beneficial antidepressant and/or anti-anxiety effects.


Scott Reines Photo 7

Method Of Treating Migraines And Pharmaceutical Compositions

US Patent:
2006019, Aug 31, 2006
Filed:
Mar 10, 2006
Appl. No.:
11/372694
Inventors:
Kremena Simitchieva - Basking Ridge NJ, US
Scott Reines - New Hope PA, US
Errol McKinney - Doylestown PA, US
Eric Sandquist - Doylestown PA, US
Deepak Khanna - Furlong PA, US
Richard Hargreaves - Terlings Park, GB
International Classification:
A61K 31/421, A61K 31/415, A61K 31/365
US Classification:
514374000, 514406000, 514471000
Abstract:
A combination of a 5HTagonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.


Scott Reines Photo 8

Method Of Treating Migraines And Pharmaceutical Compositions

US Patent:
2002017, Nov 28, 2002
Filed:
Mar 26, 2002
Appl. No.:
10/106845
Inventors:
Kremena Simitchieva - Basking Ridge NJ, US
Scott Reines - New Hope PA, US
Errol McKinney - Doylestown PA, US
Eric Sandquist - Doylestown PA, US
Deepak Khannna - Furlong PA, US
Richard Hargreaves - Terlings Park, GB
Assignee:
Merck & Co., Inc.
International Classification:
A61K031/421, A61K031/415
US Classification:
514/374000, 514/406000
Abstract:
A combination of a 5HTagonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.